Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis
Michael Sang Hughes, Suzanne Lentzsch Department of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY, USACorrespondence: Suzanne Lentzsch, Department of Hematology-Oncology, Columbia University Irving Medical Center, MH-6GN 435, 161 Fort Washington Ave, New York, NY, 1003...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-12-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/safety-and-efficacy-of-subcutaneous-daratumumab-in-systemic-al-amyloid-peer-reviewed-fulltext-article-TCRM |
| _version_ | 1827396436483899392 |
|---|---|
| author | Hughes MS Lentzsch S |
| author_facet | Hughes MS Lentzsch S |
| author_sort | Hughes MS |
| collection | DOAJ |
| description | Michael Sang Hughes, Suzanne Lentzsch Department of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY, USACorrespondence: Suzanne Lentzsch, Department of Hematology-Oncology, Columbia University Irving Medical Center, MH-6GN 435, 161 Fort Washington Ave, New York, NY, 10032, USA, Tel +1 212-305-5098, Email sl3440@cumc.columbia.eduIntroduction: Systemic AL amyloidosis, a plasma cell dyscrasia, is characterized by the production of misfolded immunoglobulin light chain. These misfolded proteins aggregate into amyloid fibrils and deposit throughout the body, resulting in widespread organ dysfunction and ultimately death. Achieving rapid and maximal elimination of the plasma cell clone is crucial to long-term survival. Daratumumab, an anti-CD38 monoclonal antibody delivered intravenously, has been swiftly incorporated into standard first-line treatment regimens. A novel formulation of daratumumab has been developed that can be injected subcutaneously.Areas Covered: As a retrospective qualitative review of prior publications involving daratumumab, this work briefly summarizes the existing data regarding the safety and efficacy of subcutaneous (SC) daratumumab, compared to intravenous (IV) daratumumab. SC daratumumab appears to deliver the same disease benefit as IV daratumumab to patients with decreased infusion-related reactions (IRRs), decreased time for administration, and similar rates of adverse events (AEs) intrinsically related to daratumumab.Expert Opinion: SC daratumumab is preferred over IV daratumumab, but the clinical situation ultimately should determine route of administration. Further investigation into cost-effectiveness benefit is warranted. Keywords: plasma cell dyscrasia, daratumumab, AL amyloidosis, adverse events, AE |
| first_indexed | 2024-03-08T18:50:55Z |
| format | Article |
| id | doaj.art-5f739f70a9c5499dbd9a9d3b5e916630 |
| institution | Directory Open Access Journal |
| issn | 1178-203X |
| language | English |
| last_indexed | 2024-03-08T18:50:55Z |
| publishDate | 2023-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj.art-5f739f70a9c5499dbd9a9d3b5e9166302023-12-28T18:07:23ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2023-12-01Volume 191063107489349Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL AmyloidosisHughes MSLentzsch SMichael Sang Hughes, Suzanne Lentzsch Department of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY, USACorrespondence: Suzanne Lentzsch, Department of Hematology-Oncology, Columbia University Irving Medical Center, MH-6GN 435, 161 Fort Washington Ave, New York, NY, 10032, USA, Tel +1 212-305-5098, Email sl3440@cumc.columbia.eduIntroduction: Systemic AL amyloidosis, a plasma cell dyscrasia, is characterized by the production of misfolded immunoglobulin light chain. These misfolded proteins aggregate into amyloid fibrils and deposit throughout the body, resulting in widespread organ dysfunction and ultimately death. Achieving rapid and maximal elimination of the plasma cell clone is crucial to long-term survival. Daratumumab, an anti-CD38 monoclonal antibody delivered intravenously, has been swiftly incorporated into standard first-line treatment regimens. A novel formulation of daratumumab has been developed that can be injected subcutaneously.Areas Covered: As a retrospective qualitative review of prior publications involving daratumumab, this work briefly summarizes the existing data regarding the safety and efficacy of subcutaneous (SC) daratumumab, compared to intravenous (IV) daratumumab. SC daratumumab appears to deliver the same disease benefit as IV daratumumab to patients with decreased infusion-related reactions (IRRs), decreased time for administration, and similar rates of adverse events (AEs) intrinsically related to daratumumab.Expert Opinion: SC daratumumab is preferred over IV daratumumab, but the clinical situation ultimately should determine route of administration. Further investigation into cost-effectiveness benefit is warranted. Keywords: plasma cell dyscrasia, daratumumab, AL amyloidosis, adverse events, AEhttps://www.dovepress.com/safety-and-efficacy-of-subcutaneous-daratumumab-in-systemic-al-amyloid-peer-reviewed-fulltext-article-TCRMplasma cell dyscrasiadaratumumabal amyloidosisadverse events |
| spellingShingle | Hughes MS Lentzsch S Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis Therapeutics and Clinical Risk Management plasma cell dyscrasia daratumumab al amyloidosis adverse events |
| title | Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis |
| title_full | Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis |
| title_fullStr | Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis |
| title_full_unstemmed | Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis |
| title_short | Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis |
| title_sort | safety and efficacy of subcutaneous daratumumab in systemic al amyloidosis |
| topic | plasma cell dyscrasia daratumumab al amyloidosis adverse events |
| url | https://www.dovepress.com/safety-and-efficacy-of-subcutaneous-daratumumab-in-systemic-al-amyloid-peer-reviewed-fulltext-article-TCRM |
| work_keys_str_mv | AT hughesms safetyandefficacyofsubcutaneousdaratumumabinsystemicalamyloidosis AT lentzschs safetyandefficacyofsubcutaneousdaratumumabinsystemicalamyloidosis |